Core Viewpoint - The livestock farming sector is experiencing a positive trend, with an extended profit period expected for pig farming, driven by improved demand and favorable pricing dynamics [1][2]. Group 1: Market Performance - As of May 7, 2025, the China Livestock Breeding Index (930707) increased by 0.20%, with key stocks such as Shengnong Development (002299) rising by 1.89% and Yiduoli (300381) by 1.75% [1]. - The Livestock ETF (516760) rose by 0.16%, with a recent price of 0.63 yuan, and has seen a cumulative increase of 7.19% over the past three months, ranking in the top 25% among comparable funds [1]. - The average price of pork in national wholesale markets reached 20.96 yuan/kg on May 6, 2025, marking a 1.8% increase compared to pre-holiday levels [1]. Group 2: Financial Performance - In 2024, pig farming enterprises are projected to generate revenues of 437 billion yuan, a year-on-year decline of 1.28%, while net profit attributable to shareholders is expected to rise by 337.73% to 32 billion yuan [1]. - In Q1 2025, pig farming enterprises achieved revenues of 107.88 billion yuan, reflecting an 18.69% year-on-year increase, with industry net profit reaching 7.91 billion yuan, up 236.12% year-on-year [1]. Group 3: Supply and Demand Dynamics - As of Q2 2025, domestic demand for pigs is showing marginal improvement, with price support and a gradual transition into a phase of price increases [2]. - External factors, including rising feed raw material prices due to tariffs and increased costs of imported meat, are also contributing to favorable pricing for pigs [2]. Group 4: Valuation Metrics - The Livestock ETF, which tracks the China Livestock Breeding Index, has a current price-to-earnings ratio (PE-TTM) of 12.38, placing it in the 1.74% percentile over the past year, indicating a valuation lower than 98.26% of the time in the last year [2]. - The China Livestock Breeding Index includes companies involved in livestock feed, veterinary drugs, and livestock farming, reflecting the overall performance of related listed companies [2]. Group 5: Top Weighted Stocks - As of April 30, 2025, the top ten weighted stocks in the China Livestock Breeding Index include Haida Group (002311), Muyuan Foods (002714), and Wens Foodstuff Group (300498), collectively accounting for 69.38% of the index [2].

民生证券股份有限公司 关于广东溢多利生物科技股份有限公司 公开发行可转换公司债券和向特定对象发行股票项目之 募投项目结项并将节余募集资金永久补充流动资金 及注销募集资金专户的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为广东 溢多利生物科技股份有限公司（以下简称"溢多利"或"公司"）公开发行可转 换公司债券和向特定对象发行股票的保荐机构及持续督导机构，根据《证券发行 上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《上市公司监 管指引第2号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》等相关规定，对溢 多利本次首次公开发行股票募集资金使用完毕及注销募集资金专户的事项进行 了核查,具体情况如下: 一、募集资金基本情况 2018年11月2日经中国证券监督管理委员会的《关于核准广东溢多利生物科 技股份有限公司公开发行可转换公司债券的批复》(证监许可[2018]1625号)核准， 公司公开发行可转换公司债券66,496.77万元，期限为6年，扣除承销及保荐费及 其他费用共计人民币2,035.35万元后，净募集资金共 ...

Group 1: Company Overview - The company operates in eight major application areas: animal nutrition and health, human nutrition and health, care and cleaning, bioenergy, food and beverage, pulp and paper, textiles and leather, and environmental and ecological agriculture [2][3]. Group 2: Financial Performance - In 2024, the company achieved a revenue of 826 million CNY, a year-on-year increase of 3.79%, and a net profit of 31.09 million CNY, marking a turnaround from losses [3][6]. - In Q1 2025, the company reported a revenue of 202 million CNY, a year-on-year growth of 1.79%, but a net profit of 4.87 million CNY, which represents a decline of 75.19% compared to the previous year [3][6]. Group 3: Operational Efficiency - The company implemented "cost reduction and efficiency enhancement" strategies, resulting in decreased production and procurement costs, thereby improving product competitiveness [3][6]. - The company has established multiple intelligent production bases in Guangdong, Inner Mongolia, and Hunan, enhancing its operational capabilities [4][6]. Group 4: Research and Development - The company has significantly increased R&D investment, achieving breakthroughs in various enzyme products and securing 22 patents across Asia, Europe, and America [5][6]. - Future growth will focus on three main areas: bio-enzymes, plant extracts, and biosynthetic products, emphasizing innovation, market expansion, and cost efficiency [6][9]. Group 5: Industry Outlook - The bio-manufacturing sector is expected to experience sustained high-quality growth, supported by national policies aimed at advancing technology and industry development [9]. - The livestock industry in China is stabilizing, with a shift towards centralized farming practices, which is anticipated to contribute to overall industry stability [9].

广东溢多利生物科技股份有限公司 第八届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 广东溢多利生物科技股份有限公司（以下简称"公司"）第八届监事会第 十次会议于 2025 年 4 月 22 日在公司十一楼会议室以现场方式召开。会议通知 于 2025 年 4 月 11 日以短信、邮件等方式发送至公司全体监事。会议应出席监 事 3 名，实际出席会议监事 3 名。会议由监事会主席冯丹女士主持。本次会议 符合《公司法》和《公司章程》的有关规定，会议合法有效。 二、监事会会议审议情况 股票代码：300381 股票简称：溢多利 公告编号：2025-030 三、备查文件 第八届监事会第十次会议决议。 特此公告。 广东溢多利生物科技股份有限公司 监事会 本次会议以投票表决方式审议通过了如下议案： 审议通过《关于公司〈2025 年第一季度报告〉的议案》。 经审议，监事会认为：公司《2025 年第一季度报告》的编制和审核符合法 律、法规的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存 在虚假记载、误导性陈述或者重大遗 ...

股票代码：300381 股票简称：溢多利 公告编号：2025-029 广东溢多利生物科技股份有限公司 第八届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 广东溢多利生物科技股份有限公司（以下简称"公司"）第八届董事会第 十一次会议于 2025 年 4 月 22 日在公司会议中心以现场和通讯相结合的方式 召开。会议通知于 2025 年 4 月 11 日以信息、邮件等方式发送至公司全体董 事。会议应出席董事 7 名，实际出席会议董事 7 名，公司监事、部分高级管理 人员列席了本次会议。会议由董事长陈少美先生主持。本次会议符合《公司法》 和《公司章程》的有关规定，会议合法有效。 2、第八届董事会审计委员会第七次会议决议。 根据《公司章程》的规定，本议案无需提交公司股东大会审议。 三、备查文件 1、第八届董事会第十一次会议决议； 二、董事会会议审议情况 本次会议以投票表决方式审议通过了如下议案： 审议通过《关于公司<2025 年第一季度报告>的议案》。 经审议，董事会认为：公司《2025 年第一季度报告》符合法律、 ...

Financial Performance - The company's revenue for Q1 2025 was ¥202,399,201.05, representing a 1.79% increase compared to ¥198,841,582.87 in the same period last year[5] - Net profit attributable to shareholders decreased by 75.19% to ¥4,870,526.10 from ¥19,630,209.75 year-on-year[5] - Basic and diluted earnings per share fell by 75.31% to ¥0.0099 from ¥0.0401 in the same period last year[5] - Net profit for the current period was ¥5,044,416.75, a decrease of 74.8% from ¥20,038,353.72 in the previous period[23] - The profit attributable to the parent company's shareholders was ¥4,870,526.10, down from ¥19,630,209.75, indicating a decline of 75.8%[23] - The total comprehensive income for the current period was ¥5,679,501.27, down from ¥17,191,761.29, a decrease of 66.9%[23] Cash Flow - The net cash flow from operating activities was -¥24,751,394.41, a decline of 146.70% compared to ¥52,995,539.37 in the previous year[5] - Cash inflow from operating activities totaled 205,286,219.50, a decrease of 16% compared to 244,444,481.49 in the previous period[24] - Net cash outflow from operating activities was -24,751,394.41, contrasting with a positive cash flow of 52,995,539.37 in the previous period[24] - Cash inflow from investment activities was 290,759,389.61, an increase of 11.8% from 260,060,152.19 in the previous period[25] - Net cash flow from investment activities was 44,915,743.56, recovering from a negative cash flow of -138,031,352.97 in the previous period[25] - The net increase in cash and cash equivalents was ¥24,214,405.11, a decrease of 56.92% compared to the previous year[12] - Total cash and cash equivalents at the end of the period reached 337,520,876.62, up from 308,277,166.79 in the previous period, reflecting an increase of 9.4%[25] - The impact of exchange rate changes on cash and cash equivalents was 261,805.99, compared to -3,563,363.18 in the previous period, indicating a positive shift[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,891,375,591.82, down 1.94% from ¥2,948,587,167.07 at the end of the previous year[5] - Total liabilities decreased to ¥230,027,116.88 from ¥294,388,193.40, a decline of approximately 21.9%[20] - The total equity attributable to the parent company was ¥2,617,017,580.27, slightly up from ¥2,611,511,969.65[20] - The total current assets decreased to 1,231,875,161.02 RMB from 1,283,485,205.88 RMB[18] - The total non-current assets include fixed assets valued at 873,517,025.03 RMB, down from 903,041,179.58 RMB[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,922, with no preferred shareholders having restored voting rights[13] - Zhuhai Jindadi Investment Co., Ltd. holds 29.01% of shares, amounting to 142,458,378 shares, with 37,500,000 shares pledged[13] - The number of unrestricted shares held by the top ten shareholders totals 142,458,378 shares[13] - The company has 10,887,600 shares held in the stock repurchase account[14] Investments and Projects - A total investment of 230 million RMB has been allocated for the Yiduoli Innovation Park project, focusing on biotechnology research and development[16] - The company plans to grant 6.38 million restricted stocks under the 2025 incentive plan, with an initial grant price of 3.73 RMB per share[15] Financial Expenses and Income - The company reported a 39.32% increase in financial expenses, amounting to an increase of ¥1,690,617.67 due to reduced interest income[10] - Investment income rose by 129.57% to an increase of ¥1,842,639.06, attributed to previous losses from joint ventures and newly purchased financial products[10] Research and Development - Research and development expenses were ¥22,685,597.45, compared to ¥22,000,561.50 in the previous period, reflecting an increase of 3.1%[22] Other Financial Metrics - Other comprehensive income after tax for the current period was ¥635,084.52, compared to a loss of ¥2,846,592.43 in the previous period[23] - Total operating costs amounted to ¥192,304,232.25, up from ¥185,606,812.47, reflecting a rise of approximately 3.7%[22] - The weighted average return on net assets decreased to 0.19% from 0.75% year-on-year[5] Board and Audit - The company has not yet audited its first-quarter report for the current year[26] - The board of directors of Guangdong Yiduoli Biotechnology Co., Ltd. convened on April 23, 2025, to discuss financial matters[27]

Company Overview - The company is a professional biotechnology enterprise engaged in the research, production, sales, and service of biological enzyme preparations, biosynthetic products, and plant extracts, providing comprehensive biotechnology solutions across eight major fields [6][10]. Business Segments Biological Enzyme Preparations - Biological enzyme preparations are high-efficiency, specific, and environmentally friendly catalysts widely used in various industries, including feed, food, energy, pharmaceuticals, textiles, and environmental protection. The enzyme preparation industry in China is in a growth phase, driven by government policies and increasing demand from downstream industries [6][7]. Biosynthetic Products - Biosynthetic products are created using biological technology to produce compounds with specific biological activity through metabolic pathways. The company has developed a platform for organic acid research, achieving industrialization standards at the small trial level [8]. Plant Extracts - The company offers both animal and human plant extracts, with animal extracts including various veterinary raw materials and formulations that have received national approval. These products are designed to reduce antibiotic use in animal feed, aligning with the trend towards green farming [9][15]. Industry Development Biotechnology Industry - The biotechnology sector continues to receive strong policy support from the government, with initiatives aimed at accelerating the development of strategic emerging industries, including biological manufacturing. The goal is to enhance the stability and competitiveness of the industrial supply chain [10][11]. Agricultural and Animal Husbandry Industry - China is the largest producer and consumer of pork globally, with the pig farming industry transitioning towards more centralized operations. The government has implemented measures to regulate pig production capacity, which is expected to improve profitability in the sector [13]. Market Position - The company aims to become a benchmark enterprise in the global biological enzyme preparation market and a leader in China's animal nutrition and health industry. It is the first listed company in China's biological enzyme preparation sector and the largest manufacturer in Asia [14]. Financial Highlights - The company has not needed to restate previous financial data, indicating stability in its financial reporting [16]. Shareholder Information - The company has completed the election of its eighth board of directors and supervisory board, ensuring governance continuity [18]. Recent Developments - The company has acquired a 49% stake in Germany's Victory Enzymes GmbH to enhance its overseas market presence and operational efficiency [19][20].

为完善和健全广东溢多利生物科技股份有限公司（以下简称"公司"）科学、 稳定、持续的分红机制，积极回报投资者，切实保护中小投资者的合法权益，根 据《中华人民共和国公司法》《上市公司监管指引第 3 号——上市公司现金分红》》 等相关法律、法规和规范性文件及《广东溢多利生物科技股份有限公司章程》（以 下简称"《公司章程》"）的相关规定，结合公司的盈利能力、经营发展规划、股 东回报等因素，公司董事会制定了《广东溢多利生物科技股份有限公司未来三年 股东分红回报规划（2025-2027 年）》（以下简称"本规划"），具体内容如下： 一、制定本规划考虑的因素 公司秉持可持续发展理念，在综合考虑企业盈利能力、经营发展规划、股东 意愿、社会资金成本以及外部融资环境等因素的基础上，建立对投资者持续、稳 定、科学的回报规划与机制，从而对股利分配作出制度性安排，以保证股利分配 政策的连续性和稳定性。 广东溢多利生物科技股份有限公司 未来三年股东分红回报规划（2025-2027 年） 二、本规划的制定原则 公司应着眼于长远可持续发展，结合公司实际经营情况、发展目标等因素， 充分考虑股东特别是中小股东、独立董事的意见，重视投资者的合理投 ...

股票代码：300381 股票简称：溢多利 公告编号：2025-022 广东溢多利生物科技股份有限公司 关于举办 2024 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 广东溢多利生物科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 19 日在巨潮资讯网（www.cninfo.com.cn）披露了《2024 年年度报告全文》及 其摘要，为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司定于 2025 年 4 月 25 日（星期五）15:00-17:00 在"价值在线（www.ir- online.cn）"举办 2024 年度业绩网上说明会，与投资者进行沟通和交流，广泛 听取投资者的意见和建议。 会议召开时间：2025 年 4 月 25 日（星期五）15:00-17:00 会议召开方式：网络文字互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 4 月 25 日 前 访 问 网 址 https://eseb. ...